secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001437749-22-026890
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q3 net loss $1.8M; SAHPRA clears Phase 1 COVID-19 vaccine trial
----------------------------------------------------------------------

- Net loss $1.809M ($0.06/share); revenue $0.88M vs $0.693M YoY increase.
- Cash and investments $14.2M; expects to fund operations into 2024.
- SAHPRA approved Phase 1 trial for DYAI-100 COVID-19 RBD booster; enrollment planned later 2022.
- R&D expenses fell to $0.744M from $1.902M YoY as pre-clinical activities wound down.
- 9x improvement in Nivolumab expression to 22.3 g/L; livestock antigen titers up to 10 g/L.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/0001437749-22-026890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774922026890/dyai20220814_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer